Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gynecologic Oncology
•
Brachytherapy
•
Medical Oncology
Is there still a role of brachytherapy in uterine cancer if intensity-modulated radiation therapy is available?
Answer from: Radiation Oncologist at Academic Institution
Yes. Brachytherapy is still more conformal than optimally planned IMRT.
Sign In
or
Register
to read more
18304
Related Questions
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
When utilizing KN-A18 protocol, how do you best address symptoms of colitis/cystitis?
Does being on maintenance pembrolizumab change how you manage patients with partial metabolic response on PET/CT 3 months after chemoradiation for cervical cancer?
For a patient with locally current endometrial cancer whose disease had complete radiographic response to carboplatin, Taxol, and pembrolizumab, would you consider adding radiation therapy?
What are your top takeaways in Gyn Cancers from ASCO 2025?
Are there patient populations in whom you would consider using both induction chemotherapy and maintenance pembrolizumab for a patient with locally advanced cervical cancer?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
How do you counsel patients about prognosis with FIGO 2018 IIIC cervix cancer managed in the new era of chemoradiation plus immunotherapy?
Would you offer systemic chemotherapy to a patient with at least 2023 FIGO stage IC high grade serous (p53-mut) endometrial cancer with extensive LVI for whom nodal assessment was not done?